Bulletin
Investor Alert

New York Markets Close in:

press release

May 14, 2021, 12:31 p.m. EDT

NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021

PITTSBURGH, May 14, May 14, 2021 (GLOBE NEWSWIRE via COMTEX) -- RBC Capital Markets Virtual Global Healthcare Conference Fireside Chat at 11:30 a.m. ET on May 19

Oppenheimer Rare & Orphan Disease Summit presentation on May 21

PITTSBURGH, May 14, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. /zigman2/quotes/206101919/composite NBSE +6.22% ("NeuBase"), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a virtual fireside chat at the RBC Capital Markets Virtual Global Healthcare Conference, as well as present a corporate overview and business update at the Oppenheimer Rare & Orphan Disease Summit, which are both being held in May 2021.

Conferences Details:

Event: RBC Capital Markets Virtual Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, May 19th
Time: 11:30 a.m. ET
Location: Webcast Link - or at the company's website ( click here )
Event: Oppenheimer Rare & Orphan Disease Summit
Format: Presentation
Date: Friday, May 21st
Location: Webcast Link - or at the company's website ( click here )

About NeuBase TherapeuticsNeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase's targeted PATrOL(TM) therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com .

NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
OP: (617) 430-7576

NeuBase Media Information:

Jessica Yingling, Ph.D.
Little Dog Communications Inc.
(858) 344-8091
jessica@litldog.com

COMTEX_386586654/2471/2021-05-14T12:31:09

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/206101919/composite
US : U.S.: Nasdaq
$ 3.85
+0.23 +6.22%
Volume: 74,255
Oct. 28, 2021 3:46p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$118.43 million
Rev. per Employee
N/A
loading...

Partner Center

Link to MarketWatch's Slice.